Introduction to Shenzhen Third People's Hospital

　　Shenzhen Third People's Hospital (the Second Affiliated Hospital of Southern University of Science and Technology), sponsored by the Shenzhen Municipal Government and founded in 1985, is a modern Grade III Class A research-oriented hospital with the development orientation of "strong specialized disciplines and comprehensive general medicine". 

　　The hospital covers an area of 213,000 square meters with a building area of 440,000 square meters (which will reach 643,000 square meters upon the completion of the Phase II expansion and renovation project and the National Research Center). It has 1,955 authorized beds and a staff of more than 2,100, including 1 Changjiang Scholar, 2 experts selected in the National Ten-Thousand Talents Program, and 3 experts enjoying the Special Government Allowance of the State Council. The hospital has independently cultivated 2 scholars funded by the National Science Fund for Distinguished Young Scholars and the first scholar funded by the National Science Fund for Excellent Young Scholars in the health system of Shenzhen. At present, it has developed into a large-scale, advanced-equipped and fully functional diagnostic, therapeutic and research center for infectious diseases in the Guangdong-Hong Kong-Macao Greater Bay Area, mainly undertaking the prevention and control of infectious diseases and major epidemics in Shenzhen and its surrounding areas while providing comprehensive medical services.

　　The hospital obtained the qualification for liver and kidney transplantation for the first time in 2017, being the first hospital in Shenzhen to attain this qualification. In 2018, it successfully passed the evaluation for Grade III Class A hospitals and was approved as a high-level hospital construction unit in Guangdong Province; it also became the Second Affiliated Hospital of Southern University of Science and Technology. In 2019, it was approved as the National Clinical Research Center for Infectious Diseases (the only one in Shenzhen and the third in Guangdong Province). In 2020, the Emergency Campus of Shenzhen Third People's Hospital was completed; the hospital was awarded the titles of Advanced Collective and Advanced Primary Party Organization in the Fight against COVID-19 in Guangdong Province, as well as Advanced Collective and Advanced Primary Party Organization of Guangdong Province and Shenzhen. It was approved as a national standardized training base for resident physicians and became the Shenzhen Center for Diagnosis and Treatment of Infectious Diseases of the Chinese Academy of Medical Sciences. For the first time, the hospital entered the top 100 hospitals in the 2020 China Hospital Rankings and was the first hospital in Shenzhen to make it to the Fudan Edition of the China's Top 100 Hospital Rankings; its tuberculosis discipline ranked 4th in the Fudan Edition of the China Hospital Specialized Discipline Comprehensive Rankings.

　　In 2021, the hospital ranked 80th nationwide (10th in Guangdong Province and the only one in Shenzhen among the top 100) in the 5-year comprehensive ASTEM ranking of the China Hospital Science and Technology Evaluation Metrics (STEM); it ranked 76th nationwide (10th in Guangdong Province and 1st in Shenzhen) in the comprehensive STEM ranking. Its tuberculosis discipline ranked 5th nationwide, infectious diseases discipline ranked 7th nationwide and both ranked 1st in Guangdong Province; respiratory medicine ranked 24th, gastroenterology ranked 46th and nursing ranked 60th nationwide.

　　In 2022, the hospital was approved as the "Major Public Service Platform for Biotherapy" by the Shenzhen Development and Reform Commission; it successfully passed the re-evaluation for Grade III Class A hospitals and the Level 6 evaluation for the functional application of the national electronic medical record system, being one of the few hospitals in China that have simultaneously passed the Level 6 evaluation for electronic medical record application and the Level 5B evaluation for hospital information interconnection and sharing. It was awarded the titles of Advanced Collective of the National Science and Technology System in the Fight against COVID-19 and Advanced Collective in the National Malaria Elimination Work; it was selected as a demonstration hospital for the reform and high-quality development of public hospitals in Guangdong Province. It ranked 100th in the 2022 China Hospital Rankings released by the Institute of Hospital Management of Fudan University, re-entering the top 100.

　　In 2023, the hospital was awarded the title of Advanced Collective of the Guangdong Medical System; it newly obtained the qualification for lung and pancreatic transplantation, becoming one of the hospitals with the most complete organ transplantation qualifications in the city and even the province. In the "2023 China Hospital Science and Technology Evaluation Metrics" released by the Chinese Academy of Medical Sciences, its tuberculosis discipline ranked 4th nationwide (up 1 place from the previous year), infectious diseases discipline ranked 11th nationwide (up 1 place from the previous year), and both ranked 1st in Guangdong Province; respiratory medicine ranked 33rd, gastroenterology ranked 40th (up 6 places), dermatology ranked 30th (up 22 places) and burn surgery ranked 99th nationwide. In the 5-year STEM (ASTEM) ranking from 2019 to 2023, the hospital's tuberculosis discipline ranked 7th, infectious diseases discipline ranked 13th, gastroenterology ranked 38th, respiratory medicine ranked 30th, dermatology ranked 52nd and burn surgery ranked 91st nationwide.

　　In 2024, the hospital newly obtained the qualification for corneal transplantation; its clinical medicine and immunology entered the top 1% of the world in the Essential Science Indicators (ESI) ranking; five experts and scholars of the hospital were selected into the list of the world’s top 2% scientists. A total of 26 individuals from the hospital have been selected into the list since its release in 2019.

　　The hospital has 56 clinical and medical technology departments, initially completing the strategic layout of "strong specialized disciplines and strong general medicine", and gradually forming a new pattern for the high-quality development of the hospital led by the "troika" of infectious medicine, organ transplantation and biotherapy. It has built a national key clinical specialty of infectious diseases and high-level key clinical specialties of Guangdong Province (Department of Infectious Diseases, Department of Tuberculosis and Department of Organ Transplantation). Relying on the National Clinical Research Center for Infectious Diseases, the national key specialty of infectious diseases and the Shenzhen Branch of the State Key Laboratory of Emerging Infectious Diseases of the University of Hong Kong, it has formed a complete disciplinary system covering subspecialties such as emerging and acute infectious diseases, tuberculosis, AIDS and liver diseases, as well as the four major drug clinical trial bases. A pattern has basically taken shape where comprehensive disciplines "feed back" infectious disease disciplines, and the hospital is gradually transforming from a Grade III Class A specialized hospital to a Grade III Class A general hospital.

　　The hospital has innovatively established a '4+4+1' scientific research system, building four integrated clinical and basic research platforms including the Shenzhen Institute of Hepatology, the Institute of Medical-Engineering Interdisciplinarity, the Transplantation Research Center and the Microbial Immunology (Emerging Infectious Diseases) Research Center. It also has four research-oriented public service platforms such as the BSL-3 Laboratory (including an SPF animal room), the biobank, the open sharing laboratory and the Biotherapy Center, and has set up a clinical research center (medical big data platform). The total value of scientific research equipment exceeds 200 million yuan. The hospital has the first top-level hybrid operating room in Shenzhen, equipped with the 4th-generation Da Vinci Surgical System; it has China's first intelligent integrated laboratory; it is also equipped with a series of modern imaging examination equipment such as the most advanced 256-slice CT, 3.0 T high-field magnetic resonance imaging (MRI), large flat-panel digital subtraction angiography (DSA) and C-arm angiography machine, mammography machine, digital dual-plate X-ray radiography system and digital gastrointestinal machine.

　　Adhering to the guidance of scientific and technological innovation and the orientation of clinical needs, the hospital has actively undertaken and participated in major research projects related to infectious diseases, carrying out research on virology, diagnostic reagent development, pathogenic mechanisms, clinical characteristics, drug and plasma therapy, and achieving a series of outstanding results: it obtained approval for China's first COVID-19 neutralizing antibody combination therapy drug with independent intellectual property rights, successfully supported the clinical application of COVID-19 treatment drugs such as ritonavir tablets, and promoted the launch of the first domestic ECMO. Since 2018, the hospital has taken the lead in releasing 18 expert consensuses and presided over 101 national-level research projects including major special projects of the Ministry of Science and Technology, such as 1 major research plan of the National Natural Science Foundation of China (NSFC), 1 exploration plan project of the NSFC, 3 project-level projects of the National Key R&D Program, 1 National Science Fund for Distinguished Young Scholars, 1 National Science Fund for Excellent Young Scholars and 1 project-level item of the National Science and Technology Innovation 2030 Major Project. The hospital has published 649 SCI papers in top international journals as the first or corresponding author, with a total impact factor of over 5,419, including 142 papers with an IF＞10 and 32 papers with an IF＞30.

　　In the future, with the goal of building a world-class and globally leading hospital, Shenzhen Third People's Hospital will construct a national clinical research center for infectious diseases and a national comprehensive regional medical center integrating medical treatment, teaching, scientific research, prevention, early warning and prediction, in accordance with the standards of internationalized medical services, modernized environmental facilities, refined medical care, standardized diagnosis and treatment processes and intelligent operation and management. It will also form an integrated innovation and development model of "disciplines – talents – projects – platforms – achievements – products".